TLDR EGFR inhibitors can cause skin issues, and managing these is important for treatment success.
Epidermal growth factor receptor inhibitors were effective in clinical cancer treatment but often caused skin-related toxic reactions, including acneiform rash, skin dryness, fissures, telangiectasia, pigmentation, hair changes, and paronychia. Actively treating these rashes and selecting appropriate medications were crucial for patients to continue anti-cancer therapy. The document summarized the clinical manifestations and treatment status of skin toxic reactions caused by these inhibitors to explore new treatment strategies.
179 citations
,
October 2018 in “American Journal of Clinical Dermatology” Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.
29 citations
,
September 2017 in “Oncology and therapy” The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.
15 citations
,
February 2017 in “Nursing Clinics of North America” Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.
43 citations
,
January 2014 in “Indian Journal of Dermatology” EGFR inhibitors can cause skin issues like acne and dryness, but these can be managed without stopping treatment.
29 citations
,
January 2012 in “Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy” New cancer drugs often cause skin and nail problems.
33 citations
,
June 2009 in “Journal of Cutaneous Pathology” Erlotinib can cause nonscarring hair loss and itchy skin.